文献速递乳腺癌

治疗效能评分:基于连续残留肿瘤负荷比较乳腺癌随机试验组新辅助化疗疗效的指标

Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
PubMed 文献 · Ann Oncol · 2022-05-02

研究开发了治疗效能评分(TES),通过比较两组残留肿瘤负荷(RCB)值的加权累积分布函数差异来量化细胞毒性疗效差异。TES在I-SPY2试验的11个实验组和对照组(n=947)中验证,能识别pCR率更高但未减少高RCB值的方案为效果较差,且TES与生存的相关性高于pCR率差异与生存的相关性。

要点

  • TES反映两组RCB值累积分布函数之间的加权面积,TES越高表示实验组向低RCB值偏移越大。
  • 在验证集中,TES可识别pCR率更高但未降低高RCB值频率的方案为效果较差。
  • TES与生存的相关性高于pCR率差异与生存的相关性。

核心结论

  • TES量化了试验组间整个病理反应分布的差异,可能作为比单纯pCR率差异更好的早期替代指标来预测试验组间生存差异。

研究设计与样本

  • 基于I-SPY2试验的durvalumab+olaparib组(n=72)及相应对照组(n=282)开发TES,其余11个实验组和对照队列(n=947)作为验证集评估TES性能。

主要发现

  • 在验证集中,TES识别出pCR率更高的组,但若治疗未减少高RCB值的频率,即使pCR率改善,TES也能更准确地识别出效果较差的方案。
  • TES与生存的相关性高于pCR率差异与生存的相关性。

关键数值与推荐

  • TES基于改良Kolmogorov-Smirnov检验并加入权重函数以捕捉高RCB值的重要性,采用两个分布函数差异下的面积作为统计指标。
  • TES越高表示实验组向低RCB值偏移越大。
  • 采用置换检验评估显著性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Difference in pathologic complete response (pCR) rate after neoadjuvant chemotherapy does not capture the impact of treatment on downstaging of residual cancer in the experimental arm. We developed a method to compare the entire distribution of residual cancer burden (RCB) values between clinical trial arms to better quantify the differences in cytotoxic efficacy of treatments. PATIENTS AND METHODS: The Treatment Efficacy Score (TES) reflects the area between the weighted cumulative distribution functions of RCB values from two trial arms. TES is based on a modified Kolmogorov-Smirnov test with added weight function to capture the importance of high RCB values and uses the area under the difference between two distribution functions as a statistical metric. The higher the TES the greater the shift to lower RCB values in the experimental arm. We developed TES from the durvalumab + olaparib arm (n = 72) and corresponding controls (n = 282) of the I-SPY2 trial. The 11 other experimental arms and control cohorts (n = 947) were used as validation sets to assess the performance of TES. We compared TES to Kolmogorov-Smirnov, Mann-Whitney, and Fisher's exact tests to identify trial arms with higher cytotoxic efficacy and assessed associations with trial arm level survival differences. Significance was assessed with a permutation test. RESULTS: In the validation set, TES identified arms with a higher pCR rate but was more accurate to identify regimens as less effective if treatment did not reduce the frequency of high RCB values, even if the pCR rate improved. The correlation between TES and survival was higher than the correlation between the pCR rate difference and survival. CONCLUSIONS: TES quantifies the difference between the entire distribution of pathologic responses observed in trial arms and could serve as a better early surrogate to predict trial arm level survival differences than pCR rate difference alone.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Marczyk M, Mrukwa A, Yau C, et al. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022. PMID: 35513244. doi:10.1016/j.annonc.2022.04.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。